Document is current
Any future updates will be listed below
-
Authors
Bakusic, J. http://orcid.org/0000-0002-0953-6974
Vrieze, E.
Ghosh, M.
Pizzagalli, D. A.
Bekaert, B.
Claes, S.
Godderis, L.
- License Information
-
More Information
Article History
Received: 19 May 2021
Accepted: 16 July 2021
First Online: 29 July 2021
Declarations
:
: The study was approved by the UZ Leuven Medical Ethics Committee and all participants signed an informed consent prior to inclusion in the study.
: Not applicable.
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. Dr. Pizzagalli has a financial interest in BlackThorn Therapeutics, which has licensed the copyright to the Probabilistic Reward Task through Harvard University. Dr. Pizzagalli’s interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors report no financial conflicts of interest. The other authors declare no conflict of interest.
